Last reviewed · How we verify

Nitramyl (Amyl Nitrite)

Johns Hopkins University · discontinued Small molecule

Nitramyl works by rapidly converting cyanide into a less toxic compound through a process called cytochrome c oxidase inhibition.

Nitramyl (Amyl Nitrite) is a small molecule drug in the amyl nitrite class, originally developed by Johns Hopkins University and currently owned by the same institution. It is used to treat the toxic effects of cyanide. The commercial status of Nitramyl is unclear, and it is not known whether it is patented or available as a generic. Key safety considerations include its potential for adverse effects, although specific details are not available. Further research is needed to fully understand its pharmacological properties.

At a glance

Generic nameAmyl Nitrite
SponsorJohns Hopkins University
Drug classamyl nitrite
ModalitySmall molecule
Therapeutic areaRespiratory
Phasediscontinued

Mechanism of action

Imagine your body's cells are like factories that use oxygen to make energy. Cyanide is like a poison that stops these factories from working. Nitramyl helps by converting the cyanide into a harmless compound, allowing the factories to start working again.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: